Breaking News Instant updates and real-time market news.

AKBA

Akebia

$15.48

0.51 (3.41%)

07:09
01/04/18
01/04
07:09
01/04/18
07:09

Akebia: Data in Phase 2 study consistent with findings from previous studies

Akebia Therapeutics announced top-line results from its Phase 2 study of vadadustat in patients with anemia associated with dialysis-dependent chronic kidney disease in Japan. The results are consistent with findings from previous studies of vadadustat. Akebia's partner, Mitsubishi Tanabe Pharma Corporation, is conducting a Phase 3 study of non-dialysis dependent patients in Japan and, based upon the data announced today, is expected to begin Phase 3 studies in DD-CKD patients in Japan in 2018. Under the terms of the collaboration agreement with MTPC, Akebia will receive $10M in milestone payments in conjunction with the start of the Phase 3 studies. The double-blind, placebo-controlled, dose-finding Phase 2 study was designed to evaluate the efficacy, safety and tolerability of orally-administered vadadustat in Japanese patients with anemia associated with DD-CKD. This 16-week study evaluated 60 patients during a 6-week placebo-controlled, fixed-dose period and a 10-week active treatment, dose adjustment and maintenance period. The primary efficacy endpoint was mean hemoglobin change from baseline to week 6 comparing vadadustat to placebo. Statistically significant improvements in the primary endpoint were observed in the vadadustat groups, 150 mg, 300 mg and 600 mg, compared to placebo. The data indicate a dose-response for vadadustat.

AKBA Akebia
$15.48

0.51 (3.41%)

11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
12/07/17
BTIG
12/07/17
INITIATION
Target $30
BTIG
Buy
Akebia initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Akebia with a Buy rating and a price target of $30. Hazlett says the company's development of Vadadustat - an HIF-PH inhibitor for anemia secondary to chronic kidney disease - has the potential to attain "hemoglobin control with material advantages compared to current standard-of-care injectable erythropoiesis stimulating agents". With its development partnerships in Japan and EU, the treatment is in a Phase 3 program expected for readouts in the first half of 2019.
12/07/17
12/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sogou (SOGO) initiated with an Overweight at JPMorgan. 2. Amag Pharmaceuticals (AMAG) initiated with a Neutral at B. Riley FBR. 3. Akebia (AKBA) initiated with a Buy at BTIG. 4. Synnex (SNX) initiated with a Buy at SunTrust. 5. Cancer Genetics (CGIX) initiated with a Buy at Maxim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

08:13
11/20/18
11/20
08:13
11/20/18
08:13
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$33.46

-0.38 (-1.12%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Initiation
Iron Mountain initiated  »

Iron Mountain initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOWR

Tower International

$29.99

0.51 (1.73%)

08:11
11/20/18
11/20
08:11
11/20/18
08:11
Hot Stocks
Breaking Hot Stocks news story on Tower International »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$16.51

-0.23 (-1.37%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Hot Stocks
Clovis issued second U.S. patent covering rucaparib »

Clovis Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$14.50

-1.54 (-9.60%)

08:10
11/20/18
11/20
08:10
11/20/18
08:10
Conference/Events
Bloom Energy has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

PME

Pingtan Marine Enterprise

$2.35

-0.05 (-2.08%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Pingtan Marine Enterprise announces three new vessels sailed to sea »

Pingtan Marine Enterprise…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRD

Nemaura Medical

$1.87

0.01 (0.54%)

08:09
11/20/18
11/20
08:09
11/20/18
08:09
Hot Stocks
Nemaura Medical signs exclusive license agreement with Al Danah Medical »

Nemaura Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

EQBK

Equity Bancshares

$37.02

-0.7 (-1.86%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Initiation
Equity Bancshares initiated  »

Equity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ESND

Essendant

$12.68

-0.02 (-0.16%)

08:08
11/20/18
11/20
08:08
11/20/18
08:08
Hot Stocks
Staples' affiliates extends expiration of tender offer for Essendant's shares »

Staples announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$7.84

-0.2 (-2.49%)

, BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Recommendations
General Electric, Baker Hughes analyst commentary  »

GE 'fire sale'…

GE

General Electric

$7.84

-0.2 (-2.49%)

BHGE

Baker Hughes

$23.00

-0.38 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

HJLI

Hancock Jaffe Laboratories

$2.02

(0.00%)

08:07
11/20/18
11/20
08:07
11/20/18
08:07
Hot Stocks
Hancock Jaffe Laboratories receives update on VenoValve application from INVIMA »

Hancock Jaffe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

MTEM

Molecular Templates

$4.59

-0.17 (-3.57%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Initiation
Molecular Templates initiated  »

Molecular Templates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:06
11/20/18
11/20
08:06
11/20/18
08:06
Earnings
Analog Devices sees Q1 adjusted EPS $1.28, plus or minus 7c, consensus $1.35 »

Sees Q1 revenue $1.51B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

KLIC

Kulicke & Soffa

$19.90

-0.96 (-4.60%)

08:05
11/20/18
11/20
08:05
11/20/18
08:05
Initiation
Kulicke & Soffa initiated  »

Kulicke & Soffa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
U.S. equities are getting de-FAANGed again »

U.S. equities are getting…

08:05
11/20/18
11/20
08:05
11/20/18
08:05
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

BWA

BorgWarner

$39.40

-0.345 (-0.87%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
BorgWarner management to meet with Wolfe Research »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

ADI

Analog Devices

$85.55

-3.94 (-4.40%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Earnings
Analog Devices reports Q4 adjusted EPS $1.55, consensus 1.52 »

Reports Q4 revenue $1.6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

WOW

WideOpenWest

$10.02

-0.15 (-1.47%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Conference/Events
WideOpenWest management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 27

    Nov

  • 03

    Dec

TOWR

Tower International

$29.99

0.51 (1.73%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Tower International signs MOU to sell European operations »

Tower International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVFY

Nova Lifestyle

$0.87

-0.03 (-3.33%)

08:03
11/20/18
11/20
08:03
11/20/18
08:03
Hot Stocks
Nova Lifestyle receives over $1M in orders from Barsala »

Nova LifeStyle announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

, HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Hot Stocks
Extreme Networks appoints Remi Thomas as CFO »

Extreme Networks (EXTR)…

EXTR

Extreme Networks

$6.20

-0.25 (-3.88%)

HPE

HP Enterprise

$14.83

-0.37 (-2.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

TGT

Target

$77.13

-1.9 (-2.40%)

08:02
11/20/18
11/20
08:02
11/20/18
08:02
Recommendations
Target analyst commentary  »

Target sales solid, buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Mar

CBRL

Cracker Barrel

$174.86

5.18 (3.05%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Downgrade
Cracker Barrel rating change  »

Cracker Barrel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MSFT

Microsoft

$104.62

-3.66 (-3.38%)

08:00
11/20/18
11/20
08:00
11/20/18
08:00
Options
Microsoft put buyer realizes 25% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 28

    Nov

  • 04

    Dec

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.